News from helsinn group A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

05 Dec, 2016, 13:26 GMT Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

Phase 2 study results presented at American Society of Hematology Annual Meeting on Saturday, December 3, 2016 Global Phase 3 study site recruitment...


03 Nov, 2016, 14:00 GMT Helsinn Group and MEI Pharma Announce Long-Term Survival and Response Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia Accepted for Oral Presentation at Upcoming American Society of Hematology Annual Meeting

Data to be presented on December 3, 2016; Abstract now available online Helsinn, a Swiss pharmaceutical group focused on building quality cancer care ...


10 Oct, 2016, 07:00 BST Helsinn Group Introduces Helsinn Investment Fund

~ Helsinn Group creates new investment fund in 40th anniversary year ~ ~ The new fund will focus on supporting early-stage investment opportunities...


01 Jul, 2016, 08:00 BST Helsinn Group Signs Agreement With Vifor Pharma for the Promotion and Distribution of Aloxi

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announces that the Company has signed an agreement, with Vifor ...


13 Jun, 2016, 08:00 BST Helsinn Group Hosts a Satellite Symposium on Shared Decision Making in Supportive Care, at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) Annual Meeting 2016 on June 24th

A Panel of World-renowned Experts Will Share Practical Recommendations on Best Practice in Supporting People With Cancer, Offering Advice on...


02 Jun, 2016, 11:00 BST Helsinn Group Signs Exclusive Agreement With Grünenthal Group for the Registration, Marketing, Promotion and Sales of Akynzeo® (Netupitant/Palonosetron Combo) in Chile

Helsinn, the Swiss Group focused on building quality cancer care products, and Grünenthal Group have announced today that they have signed an...


26 Apr, 2016, 13:00 BST Helsinn Healthcare SA, The University of Texas MD Anderson Cancer Center Enter Strategic Alliance to Improve Life of Patients Conducting Clinical Studies in Cancer Supportive and Palliative Care

- Collaboration Plans a Comprehensive Range of Clinical Studies to Evaluate Helsinn Commercialized and/or Under Development Pipeline Products in...


25 Apr, 2016, 11:00 BST Helsinn Group Signs Exclusive Agreement With Purdue Pharma Canada for the Distribution and Licensing Rights of Akynzeo® (Netupitant/Palonosetron Combo) in Canada

Helsinn, the Swiss Group focused on building quality cancer care products and Purdue Pharma Canada today announce that they have signed an exclusive...


11 Jan, 2016, 15:00 GMT Helsinn Celebrates its 40th Anniversary

~ 40 years helping patients achieve a better quality of life ~ Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, is...


13 Nov, 2015, 13:00 GMT Helsinn Group and Eisai Inc. Announce Inclusion of AKYNZEO® (netupitant/palonosetron) in American Society of Clinical Oncology (ASCO) Antiemetics Guideline Update

Helsinn Group and Eisai Inc. announced today that the American Society of Clinical Oncology (ASCO) has published a focused update to its clinical...


14 Oct, 2015, 15:19 BST Helsinn's AKYNZEO® (netupitant/palonosetron) Nominated Within the Category "Best Pharmaceutical Agent of the Year" at The Galien Foundation Prix Awards, New York

Helsinn Group announces that AKYNZEO® (netupitant/palonosetron) has been nominated by the Galien Foundation within the category "Best Pharmaceutical...


09 Sep, 2015, 07:00 BST Additional Data for anamorelin in ROMANA 1 and ROMANA 2 Studies Presented at 2015 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC), in Denver

Helsinn, a Swiss Group focused on building quality cancer care, announced today that additional study results from the ROMANA Phase III program were...


08 Sep, 2015, 11:22 BST Helsinn Group Signs Exclusive Agreement With BIAL for Distribution and Licence of Anamorelin in Spain, Portugal, Angola and Mozambique

Anamorelin is a novel ghrelin receptor agonist in development for the treatment of cancer anorexia-cachexia syndrome Helsinn, the Swiss Group focused ...


03 Sep, 2015, 07:00 BST Helsinn Group Signs Exclusive Agreement With Mundipharma for the Distribution and Licence of anamorelin in Switzerland and Liechtenstein

This exclusive agreement builds on broad partnerships with Mundipharma in cancer supportive care across multiple global territories Helsinn, the...


25 Jun, 2015, 07:00 BST Helsinn Group Hosts a Satellite Symposium on Best Practice in Treating Nausea in Cancer Patients, at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) Annual Meeting 2015

Helsinn Group, a Swiss Group focused on building quality cancer care, announces that tomorrow, on 26 June 2015, it is sponsoring a Satellite...


27 May, 2015, 08:00 BST The European Commission Approves ALOXI® (palonosetron HCl) Injection to Prevent Nausea and Vomiting Due to Chemotherapy in Children as Young as One Month

The European approval of ALOXI® for paediatric use follows the FDA approval in May 2014 of ALOXI® for paediatric use in the US Helsinn Group, the...


20 May, 2015, 08:00 BST Helsinn Group to Present Data at 2015 ASCO

Helsinn, a Swiss Group focused on building quality cancer care, announced today that three abstracts highlighting new study results will be presented ...


15 Apr, 2015, 13:00 BST Helsinn Group and Eisai Inc. Announce Inclusion of AKYNZEO® (netupitant/palonosetron) in 2015 NCCN® Antiemesis Guidelines

Helsinn Group and Eisai Inc. jointly announced today the decision of the National Comprehensive Cancer Network (NCCN) to include AKYNZEO® in the 2015 ...


09 Apr, 2015, 11:30 BST Helsinn Publishes Sustainability Report for its Drug Product Manufacturing and Supply Operation in Ireland

Helsinn, the Swiss Group focused on building quality cancer care, today announces the publication of the sustainability report for Helsinn's Dublin...


02 Apr, 2015, 08:00 BST Helsinn Advanced Synthesis Wins 2015 CMO Leadership Award

Helsinn manufacturing achieved a top 10% score in eight buyer perception categories Helsinn, the Swiss Group focused on building quality cancer care, ...


30 Mar, 2015, 16:02 BST Helsinn Group Receives Positive CHMP Opinion for Akynzeo® (netupitant/palonosetron) for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in the European Union

First New Fixed Dose Combination Targeting Two Key Pathways Involved in CINV Helsinn, the Swiss Group focused on building quality cancer care, today...


26 Mar, 2015, 07:00 GMT Helsinn Group Signs Exclusive Agreement With Mundipharma for Distribution and Licence of Anamorelin in China, Hong Kong and Macao

This exclusive agreement broadens Helsinn's existing partnerships for anamorelin in the area of cancer supportive care across multiple global...


09 Feb, 2015, 07:06 GMT Helsinn Group Signs Exclusive Agreement With Mundipharma for Distribution and Licensing of Netupitant/Palonosetron (NEPA) in Brazil

The exclusive agreement builds on our existing partnerships in the area of cancer supportive care across multiple global territories Helsinn, the...


12 Jan, 2015, 06:00 GMT Helsinn Reaches Settlement Agreement Regarding Patent Dispute on ALOXI®

Helsinn Healthcare SA announces that it has entered into a settlement agreement with Sandoz Inc. to resolve their patent litigations relating to...


27 Sep, 2014, 08:00 BST Pivotal Phase III Trial Data for Anamorelin in ROMANA 1 and 2 Studies in Non-Small Cell Lung Cancer Patients with Anorexia-Cachexia Shows Significant Increase in Lean Body Mass, Body Weight and Improved Symptoms

The Helsinn Group, a Company focused on building quality cancer care, announces that anamorelin, its novel, once-daily ghrelin receptor agonist...